• Something wrong with this record ?

Genetic and functional analyses do not explain the association of high PRC1 expression with poor survival of breast carcinoma patients

V. Brynychova, M. Ehrlichova, V. Hlavac, V. Nemcova-Furstova, V. Pecha, J. Leva, M. Trnkova, M. Mrhalova, R. Kodet, D. Vrana, J. Kovar, R. Vaclavikova, I. Gut, P. Soucek,

. 2016 ; 83 (-) : 857-864. [pub] 20160806

Language English Country France

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17013462

Grant support
NT14056 MZ0 CEP Register
NT14055 MZ0 CEP Register
NV15-25618A MZ0 CEP Register

Microtubules are vitally important for eukaryotic cell division. Therefore, we evaluated the relevance of mitotic kinesin KIF14, protein-regulating cytokinesis 1 (PRC1), and citron kinase (CIT) for the prognosis of breast carcinoma patients. Transcript levels were assessed by quantitative real-time PCR in tissues from two independent groups of breast carcinoma patients and compared with clinical data. Tissue PRC1 protein levels were estimated using immunoblotting, and the PRC1 tagged haplotype was analyzed in genomic DNA. A functional study was performed in MDA-MB-231 cells in vitro. KIF14, PRC1, and CIT transcripts were overexpressed in tumors compared with control tissues. Tumors without expression of hormonal receptors or high-grade tumors expressed significantly higher KIF14 and PRC1 levels than hormonally-positive or low-grade tumors. Patients with high intra-tumoral PRC1 levels had significantly worse disease-free survival than patients with low levels. PRC1 rs10520699 and rs11852999 polymorphisms were associated with PRC1 transcript levels, but not with patientś survival. Paclitaxel-induced PRC1 expression, but PRC1 knockdown did not modify the paclitaxel cytotoxicity in vitro. PRC1 overexpression predicts poor disease-free survival of patients with breast carcinomas. Genetic variability of PRC1 and the protein interaction with paclitaxel cytotoxicity do not explain this association.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013462
003      
CZ-PrNML
005      
20201013141242.0
007      
ta
008      
170413s2016 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2016.07.047 $2 doi
035    __
$a (PubMed)27505863
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Brynychová, Veronika $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Plzen, Charles University in Prague, Plzen, Czech Republic. $7 xx0323150
245    10
$a Genetic and functional analyses do not explain the association of high PRC1 expression with poor survival of breast carcinoma patients / $c V. Brynychova, M. Ehrlichova, V. Hlavac, V. Nemcova-Furstova, V. Pecha, J. Leva, M. Trnkova, M. Mrhalova, R. Kodet, D. Vrana, J. Kovar, R. Vaclavikova, I. Gut, P. Soucek,
520    9_
$a Microtubules are vitally important for eukaryotic cell division. Therefore, we evaluated the relevance of mitotic kinesin KIF14, protein-regulating cytokinesis 1 (PRC1), and citron kinase (CIT) for the prognosis of breast carcinoma patients. Transcript levels were assessed by quantitative real-time PCR in tissues from two independent groups of breast carcinoma patients and compared with clinical data. Tissue PRC1 protein levels were estimated using immunoblotting, and the PRC1 tagged haplotype was analyzed in genomic DNA. A functional study was performed in MDA-MB-231 cells in vitro. KIF14, PRC1, and CIT transcripts were overexpressed in tumors compared with control tissues. Tumors without expression of hormonal receptors or high-grade tumors expressed significantly higher KIF14 and PRC1 levels than hormonally-positive or low-grade tumors. Patients with high intra-tumoral PRC1 levels had significantly worse disease-free survival than patients with low levels. PRC1 rs10520699 and rs11852999 polymorphisms were associated with PRC1 transcript levels, but not with patientś survival. Paclitaxel-induced PRC1 expression, but PRC1 knockdown did not modify the paclitaxel cytotoxicity in vitro. PRC1 overexpression predicts poor disease-free survival of patients with breast carcinomas. Genetic variability of PRC1 and the protein interaction with paclitaxel cytotoxicity do not explain this association.
650    _2
$a nádory prsu $x genetika $x patologie $7 D001943
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a proteiny buněčného cyklu $x genetika $x metabolismus $7 D018797
650    _2
$a buněčná smrt $x účinky léků $7 D016923
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    12
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a genový knockdown $7 D055785
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a paclitaxel $x farmakologie $7 D017239
650    _2
$a polymorfismus genetický $7 D011110
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ehrlichová, Marie $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Plzen, Charles University in Prague, Plzen, Czech Republic. $7 xx0067467
700    1_
$a Hlaváč, Viktor $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Plzen, Charles University in Prague, Plzen, Czech Republic. $7 xx0270481
700    1_
$a Fürstová, Vlasta $u Division of Cell & Molecular Biology, 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 _AN058812
700    1_
$a Pecha, Václav, $u Institute for the Care for Mother and Child, Prague, Czech Republic. $d 1948- $7 xx0103675
700    1_
$a Levá, Jelena $u Institute for the Care for Mother and Child, Prague, Czech Republic. $7 _AN072344
700    1_
$a Trnková, Markéta $u Biolab Praha, k.s., Prague, Czech Republic. $7 xx0158385
700    1_
$a Mrhalová, Marcela $u Department of Pathology and Molecular Medicine, Motol University Hospital, Prague, Czech Republic. $7 xx0062381
700    1_
$a Kodet, Roman, $u Department of Pathology and Molecular Medicine, Motol University Hospital, Prague, Czech Republic. $d 1953- $7 nlk19990073380
700    1_
$a Vrána, David $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic. $7 xx0103187
700    1_
$a Kovar, Jan $u Division of Cell & Molecular Biology, 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Václavíková, Radka $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic. $7 xx0142918
700    1_
$a Gut, Ivan, $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic. $d 1936- $7 xx0060370
700    1_
$a Souček, Pavel $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Biomedical Centre, Faculty of Medicine in Plzen, Charles University in Prague, Plzen, Czech Republic. Electronic address: pavel.soucek@szu.cz. $7 xx0060511
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 83, č. - (2016), s. 857-864
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27505863 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20201013141239 $b ABA008
999    __
$a ok $b bmc $g 1199927 $s 974240
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 83 $c - $d 857-864 $e 20160806 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
GRA    __
$a NT14056 $p MZ0
GRA    __
$a NT14055 $p MZ0
GRA    __
$a NV15-25618A $p MZ0
LZP    __
$a Pubmed-20170413
Back

Find record

Citation metrics

Archiving options